Sign In to View Organizational & Contract Pricing.
Select a Size
About This Item
Empirical Formula (Hill Notation):
C17H22N4O2
CAS Number:
Molecular Weight:
314.38
UNSPSC Code:
51111800
PubChem Substance ID:
NACRES:
NA.77
MDL number:
Product Name
Resiquimod, ≥98% (HPLC)
SMILES string
CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O
InChI
1S/C17H22N4O2/c1-4-23-9-13-20-14-15(21(13)10-17(2,3)22)11-7-5-6-8-12(11)19-16(14)18/h5-8,22H,4,9-10H2,1-3H3,(H2,18,19)
InChI key
BXNMTOQRYBFHNZ-UHFFFAOYSA-N
assay
≥98% (HPLC)
form
powder
storage condition
desiccated
protect from light
color
white to tan
solubility
DMSO: 10 mg/mL, clear (warmed to 60 °C)
shipped in
wet ice
storage temp.
−20°C
Quality Level
Related Categories
Application
Resiquimod has been used in the stimulation of bone marrow-derived dendritic cells (BMDCs) stimulation( and B cells. It has also been used as a ligand for toll-like receptors (TLR7) in malignant melanoma cell line B16F10.
Resiquimod may be used in immunological and cancer-related cell signaling studies.
Biochem/physiol Actions
Resiquimod (R-848) is a potent synthetic agonist of TLR7/TLR8 that possesses antiviral and antitumoral activities.
Resiquimod belongs to the class of imidazoquinolinamines compounds with immunomodulatory effects. Resiquimod increases the levels of cytokines such as TNF-α, IL-6 and IFN-α.
Resiquimod is 314.4 Da molecule which elicits immune function during visceral infection with L. infantum Sp. It mediates the trafficking of granulocytes, macrophages, leukocytes and dendritic cells. It is a recommended topical drug for treating skin tumors like actinic keratosis (AK) and superficial basal cell carcinoma.
Resiquimod is an agonist of toll-like receptor 7 and 8 (TLR- and TLR-8).
Features and Benefits
This compound is featured on the Cytokine Receptors (Interleukin-1 Receptor/TIR Family) page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Bridget Freyne et al.
The Journal of infectious diseases, 217(11), 1798-1808 (2018-02-08)
BCG vaccination is associated with a reduction in all-cause infant mortality in high-mortality settings. The underlying mechanisms remain uncertain, but long-term modulation of the innate immune response (trained immunity) may be involved. Whole-blood specimens, collected 7 days after randomization from
AMPK Promotes Xenophagy through Priming of Autophagic Kinases upon Detection of Bacterial Outer Membrane Vesicles
Losier TT, et al.
Cell Reports, 26(8), 2150-2165 (2019)
Suppression of innate and adaptive B cell activation pathways by antibody coengagement of FcgammaRIIb and CD19
Szili,D, et al.
MAbs, 6(4), 991-999 (2014)
Matthew S Block et al.
Melanoma research, 29(4), 420-427 (2018-12-07)
A vaccine that could expand melanoma-specific T cells might reduce the risk of recurrence of resected melanoma and could provide an alternative or adjunct to standard immunotherapy options. We tested the safety and immunogenicity of a vaccine coupling a melanoma-associated
Paeonol ameliorates imiquimod-induced psoriasis-like skin lesions in BALB/c mice by inhibiting the maturation and activation of dendritic cells
Meng Y, et al.
International Journal of Molecular Medicine, 39(5), 1101-1110 (2017)
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service